Patent intelligence · US
US 9597302
Combination of dofetilide and mexiletine for the prevention and treatment of atrial fibrillation
Combination of dofetilide and mexiletine for the prevention and treatment of atrial fibrillation
Patent details — US 9597302
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 21, 2017
- Expiration
- Mar 16, 2037
- Applicant
- Heart Rhythm Solutions, Inc.
- Claims
- 19
- CPC classes
- A61K, A61K31/138, A61K31/18, A61K9/0053
Quick answer
US 9597302 (Combination of dofetilide and mexiletine for the prevention and treatment of atrial fibrillation) is held by Heart Rhythm Solutions, Inc.. Status: granted. Granted Mar 21, 2017. Expires Mar 16, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Heart Rhythm Solutions, Inc.
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61K, A61K31/138, A61K31/18, A61K9/0053, A61K9/48, A61P
More from Heart Rhythm Solutions, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12285460
Pharmaceutical compositions
granted -
US 12263202
Method of treating melanocortin-4 receptor pathway-associated disorders
granted -
US 12077612
Peptide compositions
granted -
US 11702448
Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers
granted -
US 11129869
Pharmaceutical compositions
granted -
US 10960046
Method of treating melanocortin-4 receptor pathway-associated disorders
granted -
US 10954268
Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers
granted -
US 10858399
Peptide compositions
granted
Frequently asked questions
What is US patent 9597302?
US 9597302 (Combination of dofetilide and mexiletine for the prevention and treatment of atrial fibrillation) is held by Heart Rhythm Solutions, Inc.. Status: granted. Granted Mar 21, 2017. Expires Mar 16, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9597302?
Heart Rhythm Solutions, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 12 pharmaceutical patents for this assignee.
When does US 9597302 expire?
Our index shows an expiration date of Mar 16, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.